Drug Overview
Spiriva (tiotropium; Boehringer Ingelheim) is a long-acting muscarinic antagonist (LAMA) approved for use in chronic obstructive pulmonary disease (COPD), and is available in a dry-powder inhaler (HandiHaler) and soft mist inhaler (Respimat) device. Spiriva exhibits pharmacological effects in the airways through inhibition of M1 and M3 receptors at the smooth muscle, leading to bronchodilation. It is indicated for the long-term treatment of COPD-associated bronchospasm and for the management of exacerbations. Spiriva was the first LAMA on the market, making it the gold-standard monotherapy in COPD. It is also approved for use in asthma.
Spiriva (tiotropium; Boehringer Ingelheim) is a long-acting muscarinic antagonist (LAMA) approved for use in chronic obstructive pulmonary disease (COPD), and is available in a dry-powder inhaler (HandiHaler) and soft mist inhaler (Respimat) device. Spiriva exhibits pharmacological effects in the airways through inhibition of M1 and M3 receptors at the smooth muscle, leading to bronchodilation. It is indicated for the long-term treatment of COPD-associated bronchospasm and for the management of exacerbations. Spiriva was the first LAMA on the market, making it the gold-standard monotherapy in COPD. It is also approved for use in asthma.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Spiriva: Chronic obstructive pulmonary disease (COPD)
Spiriva: Asthma
LIST OF FIGURES
Figure 1: Spiriva for COPD – SWOT analysis
Figure 2: The authors drug assessment summary of Spiriva for COPD
Figure 3: The authors drug assessment summary of Spiriva for COPD
Figure 4: Spiriva sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Spiriva for asthma – SWOT analysis
Figure 6: The authors drug assessment summary of Spiriva in asthma
Figure 7: The authors drug assessment summary of Spiriva in asthma
Figure 8: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
Table 1: Spiriva drug profile
Table 2: Spiriva HandiHaler Phase III data in COPD
Table 3: Spiriva Respimat Phase III data in COPD
Table 4: Spiriva Respimat’s long-term Phase III TIOSPIR study against Spiriva HandiHaler
Table 5: Spiriva sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 6: Spiriva drug profile
Table 7: Spiriva pivotal trial data in asthma
Table 8: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017–26
